Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Just Reported Decreased Shorts

September 16, 2018 - By Mona Holcomb

The stock of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) registered a decrease of 32.15% in short interest. AQXP’s total short interest was 212,100 shares in September as published by FINRA. Its down 32.15% from 312,600 shares, reported previously. With 217,000 shares average volume, it will take short sellers 1 days to cover their AQXP’s short positions. The short interest to Aquinox Pharmaceuticals Inc’s float is 1.97%.

The stock decreased 2.09% or $0.06 during the last trading session, reaching $2.81. About 158,688 shares traded. Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has declined 80.33% since September 16, 2017 and is downtrending. It has underperformed by 95.95% the S&P500.

Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The company has market cap of $66.14 million. The firm primarily focuses on anti-inflammatory product candidates targeting SH2-containing inositol-5Â’-phosphatase 1 enzyme, a key regulator of a cellular signaling pathway in immune cells. It currently has negative earnings. The Company’s lead product candidate is AQX-1125, a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome, a chronic inflammatory disease of the bladder.

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Ratings Coverage

Among 4 analysts covering Aquinox Pharmaceuticals (NASDAQ:AQXP), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Aquinox Pharmaceuticals had 6 analyst reports since May 8, 2018 according to SRatingsIntel. On Thursday, June 28 the stock rating was downgraded by Canaccord Genuity to “Hold”. Canaccord Genuity maintained Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) on Monday, May 14 with “Buy” rating. The company was downgraded on Wednesday, June 27 by Cantor Fitzgerald. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, May 8. The stock has “Neutral” rating by Guggenheim on Thursday, June 28. The firm earned “Hold” rating on Thursday, June 28 by Needham.

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: